Posted by Michael Wonder on 13 Jan 2021
Leading BioSciences announces FDA fast track designation granted to LB1148 for the treatment of post-operative gastro-intestinal dysfunction associated with paediatric cardiovascular surgery
13 January 2021 - LBS expects to initiate a pivotal trial in 2021.
Leading BioSciences announced that the U.S. FDA has granted fast track Designation to LB1148 for the treatment of post-operative gastro-intestinal dysfunction associated with paediatric heart surgery.
